• Patient-Derived Gastric Cancer Assembloids: Modeling Tumor-S

  2026-04-13

  This study introduces a patient-derived gastric cancer assembloid model that integrates matched tumor organoids and stromal cell subpopulations, recapitulating the complexity of the tumor microenvironment. By enabling more physiologically relevant drug screening and mechanistic studies, this innovation provides a robust platform for investigating resistance mechanisms and advancing personalized therapeutic strategies in gastric cancer.

• Tioconazole in Antifungal Assays: Protocols, Models, and Tip

  2026-04-13

  Tioconazole is a gold-standard antifungal medication, prized for its high purity and validated performance in in vitro antifungal assays and fungal infection models. This article delivers applied workflows, troubleshooting insights, and the latest research-backed strategies for maximizing Tioconazole’s impact in antifungal drug development.

• Pomalidomide (CC-4047): Precision Tools for Modeling Tumor H

  2026-04-12

  Explore how Pomalidomide (CC-4047) enables advanced modeling of tumor heterogeneity in hematological malignancy research. This article delivers actionable guidance for integrating genetic insights with functional assays, offering a unique framework distinct from previous content.

• Phosbind Biotin LC: Practical Guide for Phosphorylation Dete

  2026-04-12

  Phosbind Biotin LC is a phosphate-binding reagent for sequence-independent detection of phosphorylated proteins on PVDF membranes, especially in Western Blot workflows. It is best suited where phospho-specific antibodies are limiting or when detection of diverse phosphorylation sites is required. It is not recommended for aqueous-based direct applications or for samples where biotin-streptavidin detection is incompatible.

• Lenalidomide (CC-5013): Optimizing Immune Activation Workflo

  2026-04-11

  Lenalidomide (CC-5013) enables powerful immune modulation and anti-angiogenic effects in multiple myeloma research. This guide details advanced experimental setups, workflow enhancements, and troubleshooting strategies—bridging new mechanistic insights with practical, high-yield protocols.

• KN-62 Enables Precision Inhibition of Calcium Signaling Path

  2026-04-11

  KN-62, 1-[N,O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosy]-4-phenylpiperazine, is a highly selective CaMKII inhibitor that offers researchers unparalleled control over calcium signaling, secretion, and cell cycle studies. This guide unveils advanced workflows, troubleshooting strategies, and actionable protocol parameters to maximize experimental reproducibility and performance.

• BIBR 1532: Scenario-Driven Optimization for Telomerase Assay

  2026-04-10

  This article delivers a scenario-based, evidence-driven analysis of BIBR 1532 (SKU A1945) as a telomerase inhibitor for cancer research. By addressing real laboratory challenges in assay reproducibility, apoptosis induction, and product selection, it demonstrates how BIBR 1532 offers reliable, data-backed solutions that elevate experimental confidence and workflow efficiency.

• Lenalidomide (CC-5013): Workflow Optimization for Cancer ...

  2026-04-10

  Lenalidomide (CC-5013) is redefining anti-cancer drug research by enabling precise immune system activation and angiogenesis inhibition in multiple myeloma and lymphoma models. This guide delivers actionable insights—from optimized protocols to troubleshooting tips—empowering researchers to harness the full potential of this oral thalidomide derivative. Discover how integrating lenalidomide with emerging epigenetic modulators accelerates breakthroughs in cancer immunotherapy.

• Olaparib (AZD2281): Advanced PARP Inhibitor for BRCA-Defi...

  2026-04-09

  Olaparib (AZD2281, Ku-0059436) sets the benchmark for selective PARP-1/2 inhibition, enabling precise interrogation of DNA repair pathways in BRCA-deficient and platinum-resistant cancer models. This in-depth guide explores optimized experimental workflows, troubleshooting strategies, and advanced applications that empower translational oncology research.

• STING Agonist-1: Precision Activation of Innate Immunity ...

  2026-04-08

  STING agonist-1 from APExBIO enables next-generation investigation of innate immune signaling and B cell-driven antitumor responses, especially in challenging models like esophageal squamous cell carcinoma. Its high purity, DMSO solubility, and proven utility in dissecting the STING-TRAF2-IRF4 axis make it a game-changer for immunology and immunotherapy research.

• STING agonist-1: High-Purity Small Molecule for STING Pat...

  2026-04-08

  STING agonist-1 is a validated small molecule STING pathway activator for innate immunity and inflammation research. Its precise mechanism, high purity, and robust type I interferon induction make it a reference immunology research reagent. This dossier details its mechanism, benchmarks, and integration for translational and preclinical workflows.

• Capecitabine in Tumor-Targeted Chemotherapy: Mechanistic ...

  2026-04-07

  This thought-leadership article dissects Capecitabine’s tumor-selective activation, mechanistic precision, and translational promise in the era of assembloid modeling. Integrating recent advances in organoid-stroma co-culture, we provide actionable strategies for researchers aiming to achieve next-generation chemotherapy selectivity and personalized oncology breakthroughs.

• Olaparib (AZD2281): Selective PARP-1/2 Inhibitor for BRCA...

  2026-04-07

  Olaparib (AZD2281, Ku-0059436) is a potent, selective PARP-1/2 inhibitor widely adopted in BRCA-deficient cancer research and DNA damage response assays. This article details its molecular mechanism, experimental benchmarks, and integration parameters, clarifying both its translational promise and constraints for targeted therapy studies.

• Capecitabine (SKU A8647): Reliable Solutions for Preclini...

  2026-04-06

  This article provides an in-depth, scenario-driven analysis of Capecitabine (SKU A8647) for researchers engaged in cell viability, proliferation, and cytotoxicity assays. Drawing from recent assembloid model advances and vendor benchmarking, it demonstrates how Capecitabine’s validated purity, solubility, and tumor-selective activation support reproducible, physiologically relevant results in preclinical oncology. Key insights help scientists optimize protocols and confidently select high-quality reagents for robust experimental outcomes.

• Dovitinib (TKI-258, CHIR-258): Systems-Level RTK Inhibiti...

  2026-04-06

  Explore the advanced applications of Dovitinib (TKI-258, CHIR-258) as a multitargeted receptor tyrosine kinase inhibitor, uniquely positioned for systems-level dissection of apoptosis and signal transduction in RTK-driven cancers. Discover how integrating molecular mechanism studies with translational models offers new value for cancer research.

16400 records 1/1094 page Next 12345 下5页 Last page